http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2024, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 30 Jul 2024 07:17:58 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html <p>RBC's biotech survey shows investors more bearish vs. last time.</p><p>"We recently published our 2024 RBC Biotech Halftime Report , which included an investor survey that we are publishing here as a standalone note. With the XBI dancing around the $100 mark (+12% YTD and +57% since the October ’23 lows) and a few favorable catalysts behind us (ALNY, SRPT, INSM), investors are more bearish vs. our last check-in late ’23. Only 37% think the XBI will outperform the S&P500 (vs. 55% in late ’23), only 37% will increase sector exposure (vs. 43% in late ’23), and while most investors still http://www.streetinsider.com/Analyst+Comments/RBC%27s+biotech+survey+shows+investors+more+bearish+vs.+last+time/23520965.html Tue, 30 Jul 2024 07:17:58 -0400 AGIO AMGN BBH BHVN BIIB CATX CPBP CYTK EWTX GBT IBB IDYA IMVT INSM IONS ITCI KRRO KRTX LEGN LOXO MRUS MTLX RARE REGN SGEN VKTX XBI XLRN